Illustration symbolizing Lefty-1 protecting a kidney from fibrosis.

Kidney Disease Breakthrough: Can Lefty-1 Offer New Hope?

Author's portrait.
Beau Callahan in Health & Wellness December 2025 • 4 min read.

"Research suggests Lefty-1 could mitigate the effects of TGF-β1, a key player in renal fibrosis."


Chronic kidney disease (CKD) is a growing global health challenge, affecting millions worldwide. Characterized by a gradual decline in renal function, CKD often progresses to end-stage renal disease, necessitating dialysis or kidney transplantation. A major hallmark of CKD is renal interstitial fibrosis, a process where normal kidney tissue is replaced by excessive scar tissue, ultimately impairing kidney function.

The transforming growth factor (TGF)-β family of cytokines plays a significant role in the development of renal fibrosis. Specifically, TGF-β1, a key member of this family, promotes the activation of fibroblasts, cells responsible for producing the extracellular matrix (ECM). When activated excessively, fibroblasts transform into myofibroblasts, which deposit large amounts of ECM, leading to fibrosis. Therefore, targeting TGF-β1 signaling has emerged as a promising strategy for combating renal fibrosis.

Now, researchers are turning their attention to Lefty-1, a protein involved in embryonic development and known to interact with TGF-β signaling. A recent study published in Drug Design, Development and Therapy investigates the potential of Lefty-1 to mitigate TGF-β1-induced fibroblast activation and myofibroblast differentiation in kidney cells.

What is Lefty-1 and How Does it Work?

Illustration symbolizing Lefty-1 protecting a kidney from fibrosis.

Lefty-1, short for left-right determination factor 1, is a secreted protein that plays a crucial role in regulating embryonic development. It acts as an antagonist of TGF-β signaling, meaning it can block or dampen the effects of TGF-β. Previous research has shown that Lefty-1 can inhibit TGF-β1 signaling by interfering with the phosphorylation of Smad proteins, key intracellular messengers in the TGF-β pathway.

Researchers hypothesized that Lefty-1 could prevent the activation and proliferation of fibroblasts, thereby mitigating the development of renal fibrosis. To test this hypothesis, they conducted a series of experiments using NRK-49F cells, a well-established model of rat kidney interstitial fibroblasts.

Here's a summary of their key findings:
  • Lefty-1 Reduces Fibroblast Activation: Treatment with Lefty-1 significantly reduced the expression of several markers associated with fibroblast activation, including collagen I(A1), alpha-smooth muscle actin (α-SMA), and fibronectin.
  • Lefty-1 Inhibits TGF-β1-Induced Proliferation: Lefty-1 inhibited the proliferation of NRK-49F cells stimulated with TGF-β1, suggesting that it can dampen the excessive cell growth associated with fibrosis.
  • Lefty-1 Modulates TGF-β/BMP Signaling Pathways: Lefty-1 altered the activity of key proteins involved in TGF-β and bone morphogenetic protein (BMP) signaling. Specifically, it reduced the levels of Smad3 and JNK-3, while increasing the expression of BMP-5, an antifibrotic factor.
These findings suggest that Lefty-1 can alleviate TGF-β1-mediated activation and proliferation of fibroblasts, potentially preventing their differentiation into myofibroblasts. The researchers propose that Lefty-1 exerts its effects, at least in part, by modulating the activity of Smad3, JNK-3, and BMP-5 in the TGF-β/BMP signaling pathway.

The Future of Lefty-1 in Kidney Disease Treatment

This study provides valuable insights into the potential of Lefty-1 as a therapeutic target for renal fibrosis. While further research is needed to fully elucidate the mechanisms of action and to assess the efficacy and safety of Lefty-1-based therapies in vivo, these findings offer a promising avenue for developing new treatments for chronic kidney disease. Further investigation into Lefty-1 and its role in kidney health could pave the way for innovative strategies to combat renal fibrosis and improve outcomes for patients with CKD.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What is chronic kidney disease, and what is renal interstitial fibrosis?

Chronic kidney disease (CKD) is characterized by a gradual decline in renal function. Renal interstitial fibrosis, a major hallmark of CKD, involves the replacement of normal kidney tissue with excessive scar tissue, impairing kidney function. This process often leads to end-stage renal disease, requiring dialysis or kidney transplantation.

2

What is the role of TGF-β1 in the development of renal fibrosis?

TGF-β1, a member of the transforming growth factor (TGF)-β family of cytokines, plays a significant role in renal fibrosis. It promotes the activation of fibroblasts, cells responsible for producing the extracellular matrix (ECM). Excessive activation leads fibroblasts to transform into myofibroblasts, depositing large amounts of ECM and causing fibrosis. Targeting TGF-β1 signaling is a promising strategy for combating renal fibrosis.

3

What is Lefty-1, and how does it work to potentially combat kidney fibrosis?

Lefty-1, or left-right determination factor 1, is a secreted protein involved in regulating embryonic development. It acts as an antagonist of TGF-β signaling, blocking or dampening its effects. Lefty-1 can inhibit TGF-β1 signaling by interfering with the phosphorylation of Smad proteins, which are key intracellular messengers in the TGF-β pathway. This suggests it can prevent fibroblast activation and proliferation, mitigating renal fibrosis.

4

What are the key research findings regarding the effects of Lefty-1 on kidney cells?

Research indicates that Lefty-1 reduces fibroblast activation by decreasing the expression of markers like collagen I(A1), alpha-smooth muscle actin (α-SMA), and fibronectin. It also inhibits TGF-β1-induced proliferation of kidney cells, suggesting it can dampen excessive cell growth associated with fibrosis. Furthermore, Lefty-1 modulates the TGF-β/BMP signaling pathways by reducing levels of Smad3 and JNK-3, while increasing the expression of BMP-5, an antifibrotic factor.

5

Why is Lefty-1's modulation of the TGF-β/BMP signaling pathway important?

Lefty-1's ability to modulate the TGF-β/BMP signaling pathway is significant because it affects key proteins involved in fibrosis. By reducing Smad3 and JNK-3 levels and increasing BMP-5 expression, Lefty-1 can potentially prevent fibroblasts from differentiating into myofibroblasts. This modulation suggests a targeted approach to alleviating TGF-β1-mediated activation and proliferation of fibroblasts, offering a promising therapeutic avenue.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.